

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23L 1/30, A23D 7/00 // A23C 9/152	A1	(11) International Publication Number: WO 97/46118
		(43) International Publication Date: 11 December 1997 (11.12.97)

(21) International Application Number: PCT/US97/04537

(22) International Filing Date: 19 March 1997 (19.03.97)

(30) Priority Data:
08/659,845 7 June 1996 (07.06.96) US

(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; P.O. Box 7365, Madison, WI 53707-7365 (US).

(72) Inventors: COOK, Mark, E.; 15 Kewaunee Court, Madison, WI 53705 (US). PARIZA, Michael, W.; 7102 Valhalla Trail, Madison, WI 53719 (US).

(74) Agent: KRYSHAK, Thad; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: DIETETIC FOODS CONTAINING CONJUGATED LINOLEIC ACIDS

(57) Abstract

A dietetic food which contains a safe and effective amount of conjugated linoleic acid (CLA).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DIETETIC FOODS CONTAINING CONJUGATED LINOLEIC ACIDS

Field of the Invention

The present invention generally relates to human nutrition. More particularly, it relates to dietetic foods for animals, especially humans.

Background of the Invention

Dietetic foods are synthetic foods specifically formulated for people on restricted diets. Such foods, which can contain natural foods as ingredients, can take the form of either enteral compositions or parenteral compositions.

10 Enteral compositions are compositions for oral consumption or tubal feeding intended to replace natural food products that cause or aggravate allergies or other conditions in some individuals. Some common examples of enteral compositions are the baby formulae which do not contain milk proteins and
15 margarines intended for heart patients.

Parenteral compositions are compositions for intra-venous administration to patients. Usually they are used with patients who have difficulty with orally administered food. Some common examples of parenteral compositions are solutions
20 of electrolytes, proteins, carbohydrates and fats.

We have discovered that it is advantageous for humans to consume more conjugated linoleic acids (CLA) than are provided in dietetic foods. It is especially important that humans who are on restricted diets and consume only dietetic foods
25 receive conjugated linoleic acid because such diets can be totally lacking in the CLA which can be found in some natural foods which are consumed in a normal unrestricted diet.

In addition to being a good calorie source in dietetic foods, CLA can be a valuable addition to dietetic foods
30 because we have found it to be effective in increasing body protein or preventing the loss of body protein in a human, increasing food efficiency in humans, and reducing body fat. In addition, it appears to stimulate the immune system and to increase the level of CD4 and CD8 cells.

Summary of the Invention

It is an object of the present invention to disclose dietetic foods which contain conjugated linoleic acids (CLA).

We have discovered that dietetic foods which contain a
5 safe amount of an active form of a conjugated linoleic acid (CLA), such as 9,11-octadecadienoic acid and 10,12-

octadecadienoic acid, an ester thereof, a non-toxic salt thereof, and mixtures thereof, are a superior nutritional product for animals on restricted diets.

10 It will be apparent to those skilled in the art that the forementioned objects and other advantages may be achieved by the practice of the present invention.

Description of the Preferred Embodiment

The dietetic foods of the present invention contain a
15 safe and effective amount of an active form of conjugated linoleic acid (CLA) selected from a conjugated linoleic acid, such as 9,11-octadecadienoic acid and 10,12-octadecadienoic acid, an ester thereof, a non-toxic salt thereof, and mixtures thereof. These dietetic foods will also contain one or more
20 proteins, electrolytes, carbohydrates, fats, vitamins or minerals.

The amount of the CLA to be included in the dietetic food will vary with the intended use of the food and whether the dietetic food with CLA will be the sole source of nutrition.
25 However, since the CLA is a natural food ingredient and relatively non-toxic, the amount which can be consumed is not critical as long as it is enough to be effective and it is not contraindicated in the patient's diet.

The practice of the present invention is further
30 illustrated by the examples which follow:

EXAMPLE 1

Synthesis of Conjugated Linoleic Acids (CLA) From Linoleic Acid and Safflower Oil

35 Ethylene glycol (1000 g) and 500 g potassium hydroxide (KOH) are put into a 4-neck round bottom flask (5000 ml). The flask is equipped with a mechanical stirrer, a thermometer, a

reflux condenser, and a nitrogen inlet. (The nitrogen introduced in first run through two oxygen traps).

Nitrogen is bubbled into the ethylene glycol and KOH mixture for 20 min and the temperature is then raised to 180° C.

5 1000 g of linoleic acid, corn oil, or safflower oil then is introduced into the flask. The mixture is heated at 180° C under an inert atmosphere for 2.5 hours.

The reaction mixture is cooled to ambient conditions and 600 ml HCl is added to the mixture which is stirred for 15
10 min. The pH of the mixture is adjusted to pH 3. Next, 200 ml of water is added into the mixture and stirred for 5 min. The mixture is transferred into a 5 L separatory funnel and extracted three times with 500-ml portions of hexane.

The aqueous layer is drained and the combined hexane
15 solution extracted with four 250-ml portions of 5% NaCl solution.

The hexane is washed three times with water. The hexane is transferred to a flask and moisture in the hexane removed with anhydrous sodium sulfate (Na^2SO_4). The hexane is
20 filtered through Whatman paper into a clean 1000 ml round bottom flask and the hexane removed under vacuum with a rotoevaporator to obtain the CLA. The CLA is stored in a dark bottle under argon at -80° C until time of use.

This method can be modified so as to utilize only food-
25 grade reagents and solvents as listed in *Food Chemicals Codex*, third edition, National Academy Press, 1981.

The active forms of CLA include, in addition to the free acids, the non-toxic salts thereof, the active esters thereof, such as triglycerides, and mixtures thereof.

30 The free conjugated linoleic acids (CLA) have been previously isolated from fried meats and described as anticarcinogens by Y. L. Ha, N. K. Grimm and M. W. Pariza, in *Carcinogenesis*, Vol. 8, No. 12, pp. 1881-1887 (1987). Since then, they have been found in some processed cheese products.
35 Y. L. Ha, N. K. Grimm and M. W. Pariza, in *J. Agric. Food Chem.*, Vol. 37, No. 1, pp. 75-81 (1987). The free acid forms of the CLA may be prepared by isomerizing linoleic acid. The terms "conjugated linoleic acids" and "CLA" as used herein are

intended to include 9,11-octadecadienoic acid, 10,12-octadecadienoic acid; non-toxic salts thereof; esters thereof; and mixtures thereof. The non-toxic salts of the free acids may be made by reacting the free acids with a non-toxic base.

5 One method of synthesizing CLA is described in Example 1. However, CLA may also be prepared from linoleic acid by action of a linoleic acid isomerase from a harmless microorganism, such as the Rumen bacterium Butyrivibrio fibrisolvens.

10 Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic acid to CLA (S. F. Chin, J. M. Storkson, W. Liu, K. Allbright and M. W. Pariza, 1994, J. Nutr. 124; 694-701).

The CLA obtained by the practice of the described methods of preparation contains one or more of the 9,11-
15 octadecadienoic acids and/or 10,12-octadecadienoic acids and active isomers thereof. It may be free or bound chemically through ester linkages. The CLA is heat stable and can be used as is, or dried and powdered. The CLA is readily converted into a non-toxic salt, such as the sodium or potassium
20 salt, by reacting chemically equivalent amounts of the free acid with an alkali hydroxide at a pH of about 8 to 9. CLA also can be esterified to glycerol to form mono-, di-, and triglycerides.

Theoretically, 8 possible geometric isomers of 9,11- and
25 10,12-octadecadienoic acid (c9, c11; c9, t11; t9, c11; t9, t11; c10, c12; c10, t12; t10, c12 and t10, t12) would form from the isomerization of c9, c12-octadecadienoic acid. As a result of the isomerization, only four isomers (c9, c11; c9, t11; t10, c12; and c10, c12) would be expected. However, of the four isomers,
30 c9, t11- and t10, c12- isomers are predominantly produced during the autoxidation or alkali-isomerization of c9, c12-linoleic acid due to the co-planar characteristics of 5 carbon atoms around a conjugated double-bond and spatial conflict of the resonance radical. The remaining two c, c-isomers are minor
35 contributors.

The relatively higher distribution of the t, t-isomers of 9,11- or 10,12-octadecadienoic acid apparently results from the further stabilization of c9, t11- or t10, c12- geometric

isomers, which is thermodynamically preferred, during an extended processing time or long aging period. Additionally the t,t-isomer of 9,11- or 10,12-octadecadienoic acid that was predominantly formed during isomerization of linoleic acid
5 geometrical isomers (t9,t12-, c9,t12- and t9,c12-octadecadienoic acid) may influence the final ratio of the isomers or the final CLA content in the samples.

Linoleic acid geometrical isomers also influence the distribution of minor contributors (c,c-isomers of 9,11- and
10 10,12-, t9,c11- and c11,t12-octadecadienoic acids). The 11,13-isomer might be produced as a minor product from c9,c12-octadecadienoic acid or from its isomeric forms during processing.

The exact amount of CLA to be incorporated into a
15 dietetic food, of course, depends upon the intended use of the food, the form of CLA employed, and route of administration. It also can depend upon the isomer ratios. However, generally the dietetic food will contain the equivalent of about 0.5 g to about 1.0% g of CLA by weight of the dietetic food. The
20 CLA content also can be expressed as the amount of CLA based on the total calories in the serving e.g. 0.03 to 3 gram CLA per 100 calorie serving. Alternatively, the amount of CLA can be expressed as a percentage of the lipid or fat in the food, such as 0.3% to 100% of the food lipid, or as an amount of CLA
25 per gram of food lipid, such as 3 to 1000 mg CLA per gram of lipid.

When the patient's sole source of food is the dietetic food, the amount of CLA employed should be such that the patient consuming the dietetic food will obtain from about 500
30 parts per million (ppm) to about 10,000 ppm of CLA in his diet. If the dietetic food is not the sole source of food higher or lower amounts of the dietetic food might need to be consumed to reach these levels. However, the upper limit of the amount to be employed is not critical because CLA is
35 relatively non-toxic and it is a normal constituent of the human diet (including human breast milk).

The CLA to be incorporated into the dietetic food can be in the form of the free acid, a salt thereof; an ester thereof, such as a triglyceride; and any mixtures thereof.

Example 1

5 A liquid dietetic food for parenteral administration to
~~humans contains emulsified fat particles of about 0.33-0.5 μ m~~
in diameter. In addition, the emulsions can contain Water for
Injection USP as a diluent, egg phosphatides (1-2%) as an
emulsifying agent and glycerin (2-3%) to adjust toxicity.
10 These emulsions can be infused intravenously to patients
requiring parenteral nutrition. Representative formulae of
the present invention would contain the same ingredients plus
0.5 mg/gm to 10 mg/gm of CLA or alternatively, 0.3% to 100%
CLA based on the food lipid or 0.03 gram to .3 gram per 100
15 calorie serving. For such parenteral foods the CLA usually
should be present in the form of the triglycerides.

Example 2

A milk protein-free, soy protein-based, baby formula is
prepared which contains CLA. Such a baby formula will contain
20 about 0.5 mg/gram to about 10 mg/gram of CLA or about 0.03
gram to 0.5 gram CLA per 100 calorie serving or 0.3% to 100%
CLA based on the lipid in formula.

One serving (100 calories) of a representative formula
can contain the following:

25	Protein	2.66 g
	Fat	5.46 g
	Carbohydrate	10.1 g
	Water	133 g
	CLA	0.3 g
30	Vitamins and Minerals (RDA amounts)	

Example 3

A dietetic margarine of the present invention for use in
a heart-healthy diet is a semi-solid or solid vegetable oil-
based margarine which, in addition to the usual ingredients,
35 contains CLA. Such a margarine will contain about 0.25

mg/gram to about 10 mg/gm of CLA or about 0.03 gram to 0.5 gm CLA per 100 calorie serving.

Example 4

5 A low residue liquid enteral dietetic product useful as a high-protein, vitamin and mineral supplement contains added CLA. The amount of CLA present can be about 0.05% to about 5% by weight of CLA or about 0.3% to about 100% of the lipid present or about 0.03 to 0.3 gram CLA per 100 calories.

10 One serving (140 calories) of a representative formula can contain the following:

Protein (egg white solids)	7.5 g
Fat (CLA)	0.1 g
Carbohydrate (sucrose, hydrolyzed corn starch)	27.3g
15 Water	1.9 g
Vitamins and Minerals	(RDA amounts)

It will be readily apparent to those skilled in the art that many dietetic foods, including those described in U.S. Patent Nos. 4,282,265 and 5,470,839, can be improved by adding 20 CLA to the food or by replacing some of the fat in the food with CLA.

It also will be readily apparent to those skilled in the art that a number of modifications or changes may be made without departing from the spirit and scope of the present 25 invention. Therefore, the invention is only to be limited by the claims.

CLAIMS

1. A dietetic food containing a member selected from the class consisting of a conjugated linoleic acid, an ester thereof, a non-toxic salt thereof, and mixtures thereof; said member being present in amount of at least 3 mg per gram of
5 ~~lipid in the food.~~

2. A dietetic food of claim 1 in which the dietetic food is a baby formula.

3. A dietetic food of claim 1 in which the dietetic food is suitable for enteral administration.

10 4. A dietetic food of claim 1 in which the member is present as an ester and dietetic food is suitable for parenteral administration.

15 5. In a dietetic food, the improvement which comprises incorporating in said food a safe amount of a member selected from the class consisting of a conjugated linoleic acid, a salt thereof, an ester thereof, and mixtures thereof.

6. A dietetic food of claim 5 in which the amount of the member is equivalent to at least about 3.0 mg per gram of product lipid of the dietetic food.

20 7. A method of modifying a synthetic formulated dietetic food which comprises incorporating in said food at least about 3.0 mg per gram of CLA per gram of product lipid.

25 8. A dietetic food adapted for infant feeding as the sole item of diet, said food comprising assimilable carbohydrate, protein and fat, wherein the fat comprises at least about 3.0 mg of CLA per gram of fat.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/04537

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A23L1/30 A23D7/00 //A23C9/152

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A23L A23D A23C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DMZ LEBENSMITTELINDUSTRIE UND MILCHWIRTSCHAFT, vol. 116, no. 26, December 1995, pages 1268-1272, XP002035276 KAMMERLEHNER: "Linolsäure und konjugierte Linolsäuren - ihr Vorkommen im MilCHFett, ihre biologische Bedeutung" see page 1270 - page 1271; tables 1,2 --- -/--	1,3,5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

15 July 1997

Date of mailing of the international search report

24. 07. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Gac, G

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 97/04537

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF FOOD COMPOSITION AND ANALYSIS, vol. 5, 1 January 1992, pages 185-197, XP000575131 CHIN S F ET AL: "DIETARY SOURCES OF CONJUGATED DIENOIC ISOMERS OF LINOLEIC ACID, A NEWLY RECOGNIZED CLASS OF ANTICARCINOGENS" see the whole document	1-3,8
Y		5-7
A		4
X	FOOD CHEM., vol. 47, no. 3, 1993, pages 257-261, XP002035277 SANTHA ET AL.: "Conjugated linoleic acid concentrations in processed cheese containing hydrogen donors, iron and dairy-based additives" see the whole document	1,3
X	J. FOOD SCI., vol. 60, no. 4, 1995, pages 695-698,720, XP000676645 SANTHA ET AL.: "conjugated linoleic acid concentrations in dairy products as affected by processing and storage" see the whole document	1,3
X	US 5 428 072 A (COOK) 27 January 1995 see the whole document	1,5-7
X	J. DAIRY SCI., vol. 78, no. 11, 1995, pages 2358-2365, XP000676673 LIN ET AL.: "Survey of the conjugated linoleic acid contents of dairy products" see the whole document	1,3
Y		5
A		4
X	ERNÄHRUNG, vol. 19, no. 6, 1995, pages 265-270, XP000676658 SIEBER: "konjugierte Linolsäuren in Lebensmitteln: eine Übersicht" see the whole document	1,3
Y	see page 266 - page 268	5
X	NUTRITION REPORTS INTERNATIONAL, vol. 38, no. 5, November 1988, pages 937-944, XP000607841 FOGERTY A C ET AL: "OCTADEC-9,11-DIENOIC ACID IN FOODSTUFFS AND IN THE LIPIDS OF HUMAN BLOOD AND BREAST MILK" see tables I,II	1,3-5

INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/US 97/04537

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIPID TECHNOL., vol. 7, no. 6, 1995, pages 133-135, XP000677845 GURR: "A trans fatty acid that is good to eat ? conjugated linoleic acid" see page 134 left column and right column last paragraph ---	1-3,8
X	NATURE, vol. 352, 22 August 1991, page 673 XP002035278 SARKAR : "Beneficial ghee ?" see the whole document ---	1
Y	FASEB J. , vol. 10, no. 3, 8 March 1996, page a553 XP000676659 MCGUIRE: "conjugated linoleic acid concentration of human milk and infant formulae" see abstract nr 3187 ---	5-7
Y	US 5 068 119 A (KLEMAN) 26 November 1991 see column 6 lines 28-38, 44-68 see column 7, line 1 - line 5 see examples 8,9 ---	1,3-7
Y	WO 92 10105 A (NABISCO BRANDS) 25 June 1992 see page 16, line 22 see page 24, line 1 - line 10 ---	1,3,4,7
X	JP 06 276 939 A (SNOW BRAND MILK PROD. CO.) 4 October 1994	1
X	& CHEMICAL ABSTRACTS, vol. 122, no. 11, 13 March 1995 Columbus, Ohio, US; abstract no. 131629x, page 6001; XP002028553 see abstract ---	1
P,X	LIPIDS, vol. 32, no. 2, February 1997, pages 199-204, XP000676662 BELURY: "conjugated linoleic acid modulates hepatic lipid composition in mice" see the whole document -----	7
Y		1,3,5,6

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/04537

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5428072 A	27-06-95	US 5430066 A EP 0680318 A JP 8505775 T WO 9416690 A US 5504114 A US 5554646 A DE 69301693 D DE 69301693 T EP 0579901 A	04-07-95 08-11-95 25-06-96 04-08-94 02-04-96 10-09-96 11-04-96 25-07-96 26-01-94
US 5068119 A	26-11-91	NONE	
WO 9210105 A	25-06-92	EP 0560944 A JP 6506106 T US 5391383 A US 5434278 A US 5380544 A US 5378490 A US 5456939 A US 5411756 A US 5552174 A US 5565232 A US 5258197 A US 5407695 A US 5362508 A US 5380538 A US 5374440 A	22-09-93 14-07-94 21-02-95 18-07-95 10-01-95 03-01-95 10-10-95 02-05-95 03-09-96 15-10-96 02-11-93 18-04-95 08-11-94 10-01-95 20-12-94
JP 6276939 A	04-10-94	NONE	